Sfmg LLC Acquires 237 Shares of Novo Nordisk A/S (NYSE:NVO)

Sfmg LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 15.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,815 shares of the company’s stock after acquiring an additional 237 shares during the period. Sfmg LLC’s holdings in Novo Nordisk A/S were worth $216,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC grew its stake in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S in the 2nd quarter worth $25,000. Abound Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after purchasing an additional 157 shares during the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at about $28,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $108.63 on Friday. The business’s 50 day moving average price is $110.75 and its 200-day moving average price is $126.48. Novo Nordisk A/S has a fifty-two week low of $96.53 and a fifty-two week high of $148.15. The company has a market cap of $487.48 billion, a P/E ratio of 35.16, a P/E/G ratio of 1.43 and a beta of 0.40. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $150.40.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.